; and (VI) any other information determined appropriate by the Secretary. (iii) Pharmacy access to limited access drug information For plan years beginning with plan year 2026, upon the request of a network pharmacy, a PDP sponsor of a prescription drug plan shall provide such pharmacy, not later than 14 days after receiving such request, with the information described in subclauses (I), (II), and (III) of clause (ii). (iv) HHS annual report on limited access drugs Not later than December 31, 2028, and annually thereafter, the Secretary shall submit to the Committee on Finance of the Senate, and the Committee on Ways and Means and the Committee on Energy and Commerce of the House of Representatives a report on compliance by PDP sponsors with the requirements under this subparagraph. Each such report shall include— (I) a description of the patterns, trends, variations, and rationales for the designation by PDP sponsors of certain covered part D drugs as limited access drugs, and the implications of such designations on beneficiary access to such covered part D drugs; (II) a description of the information submitted to the Secretary under clause (ii) (in a manner that does not disclose the identity of a pharmacy, a PDP sponsor, a prescription drug plan, or pharmacy benefit manager, or any proprietary pricing information)